Innate Pharma S.A. (EPA:IPH)

Innate Pharma Revenue

In the year 2025, Innate Pharma had annual revenue of 9.01M EUR, down -55.25%. Innate Pharma had revenue of 4.13M in the half year ending December 31, 2025, a decrease of -80.72%.

• Revenue (ttm): 8.99M
• Revenue Growth: -55.29%
• P/S Ratio: 12.80
• Revenue / Employee: 55.25K
• Employees: 174
• Market Cap: 115.22M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	9.01M	-11.12M	-55.25%
Dec 31, 2024	20.12M	-41.52M	-67.36%
Dec 31, 2023	61.64M	3.97M	6.88%
Dec 31, 2022	57.67M	32.97M	133.47%
Dec 31, 2021	24.70M	-45.07M	-64.60%
Dec 31, 2020	69.77M	-15.68M	-18.35%
Dec 31, 2019	85.45M	-	-

Data Source: Fiscal.ai Last updated: Dec 31, 2025

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 13, 2026

Data Sources Report a data error